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Background and Objectives. Altered adhesive inter-
action between bone marrow (BM) stroma and
progenitors in chronic myeloid leukemia (CML) may
be in part caused by abnormal expression of cell
adhesion molecules (CAMs) on malignant progeni-
tor cells. Treatment of CML with interferon- (IFN-
) re-establishes normal hemopoiesis in some
patients in part by restoring normal adhesive inter-
actions between CML progenitors and BM microen-
vironment, which may in turn be mediated by cor-
recting CAM expression on progenitors. 
Design and Methods. We investigated the expres-
sion of CAMs (L-selectin, 2-integrin, LFA-3, ICAM-
1, ICAM-3, NCAM) on purified BM CD34+ cells from
CML patients (n= 34) and healthy adults (n= 15) by
flow cytometry. Modulation of L-selectin expression
on CD34+ cells from CML after in vitro treatment
with IFN- was also investigated. 
Results. The mean percentage of CD34+ cells
expressing L-selectin was significantly lower in CML
patients (25.4±12.8%) than in normal controls
(68.7±8.3%, n=15). CD34+/HLA-DR–/low and CD34+/
CD38–/low co-expressing L-selectin were also signifi-
cantly lower in untreated CML (27.4±21.5% and
39.8±26.7%, respectively, n=8) than in controls
(61±17% and 83.7±10%, respectively, n=7). In vitro
treatment with IFN- of purified CD34+ BM cells from
untreated CML patients (n=8) induced a significant,
dose and time-dependent increase in the L-selectin
expression as indicated by FACS analysis.
Interpretation and Conclusions. We hypothesize
that this L-selectin deficiency reflects a cell surface
adhesion defect of progenitors from CML that is par-
tially restored by in vitro IFN- treatment. These
data may help to explain the adhesive abnormalities
of CML progenitors to the BM microenvironment
and the in vitro restoration of adhesion capacity
after IFN- treatment. 
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Chronic myeloid leukemia (CML) is a clonalmalignancy of the hematopoietic stem cell1characterized by the Philadelphia chromosome
(Ph1).2 This disease has an initial chronic phase char-
acterized by an expanded myeloid clonal hemato-
poiesis with increased, unregulated malignant cell
proliferation and a premature release of progenitor
cells into the peripheral blood.3 Several studies have
demonstrated that Ph1+ progenitors adhere poorly
to bone marrow (BM) stroma feeders compared to
normal progenitor cells.4,5 This diminished capacity
of adhesion seems to be partially due to an abnormal
expression and/or function of cell adhesion mole-
cules (CAM) on the malignant cell surface. An abnor-
mal expression of LFA-3, 1-integrin and L-selectin
CAMs on CML progenitors has been previously
reported by other groups.6-8 Adhesion receptors
retain stem and progenitor cells within the BM
microenvironment during normal steady-state hemo-
poiesis.9-15 Moreover, interactions between hemato-
poietic progenitors and progenitor-stromal compo-
nents via adhesion molecule-ligand pairs have also
been implicated in the regulation of progenitor cell
proliferation and differentiation.9,16,17 Therefore,
diminished adhesion capacity in CML may contribute
to the premature release of progenitors into the
peripheral blood and their malignant cell growth
advantage.18, 19
Interferon- (IFN-) treatment induces a significant
reduction of the Ph1+ cells restoring residual normal
hematopoiesis in some CML patients.20-22 The mech-
anisms by which IFN- suppresses malignant hema-
topoiesis remain poorly understood. In vitro studies
have demonstrated that CML progenitors can adhere
to normal stromal layers after the treatment of the
stroma with IFN-.23 It has been also demonstrated
that IFN- acts directly on CML progenitors by restor-
ing deficient expression of LFA-38 and modulating the
function of 1-integrin receptor.7 These data suggest
that IFN- may enhance the expression of other crit-
ical adhesion molecules that are deficient on CML
progenitors, such as L-selectin.6
We investigated the co-expression of CAMs on
CD34+ BM cells from CML patients. L-selectin
(selectin family), intracellular CAM-1 and 3 (ICAM-
1 and ICAM-3), neural CAM (NCAM), leukocyte
function antigen-3 (LFA-3) (CAM immunoglobulin
family) and 2-integrin chain receptor (integrin fam-
ily) were analyzed. Here we show that,  compared to
normal controls, CD34+ cells of CML patients have
a low co-expression of L-selectin and that in vitro
treatment of CD34+ purified cells with IFN-2b is
able to modulate this deficient expression. 
Design and Methods
Patients
BM samples were obtained from 41 Ph1+ CML
patients, 26 males and 15 females, with a median
age of 44 years (range; 20-80). All patients were in
chronic phase when studied. Twenty-two patients
were studied at diagnosis before receiving any treat-
ment (untreated patients), 15 had been treated with
IFN-2b (Schering-Plough S.A., Madrid, Spain) for a
variable period of time (between 3 and 86 months,
median 12) and 4 with hydroxyurea alone. The medi-
an time between diagnosis and study was 38 (8-99)
and 47 months (1-63) in CML patients treated with
IFN- and hydroxyurea, respectively. Eight of 15 CML
patients treated with IFN- showed some degree of
cytogenetic response. The percentage of Ph1 negative
metaphases in the responding patients ranged from
10% to 100% (median 30%). The control group com-
prised BM samples from 16 healthy adult subjects,
with a median age of 46 years (range; 39-52) under-
going BM harvest for allogeneic transplantation.
Samples were obtained in accordance with the
Institutional Human Research Committee guidelines. 
CD34+ cell purification
CD34+ cells were isolated by positive selection by
magnetic activated cell sorting (mini-MACS, Miltenyi
Biotec, Gladbach, Germany) as reported elsewhere.24
Briefly, mononuclear cells (MNC) were washed twice
in Ca2+/Mg2+/red phenol free Hank’s saline solution
(HBS) and human serum albumin (HSA) 1%, pH=7.5,
after separation by Ficoll-Hypaque density gradient
(d=1.077) (Pharmacia, Sweden). Cells were diluted to
a concentration of 3108 MNC/mL in degassed HBS
with HSA 1% and ACD-A 6% (selection buffer) (Baxter,
Barcelona, Spain), pH=7.5. Cells were then filtered
through a nylon mesh (30 µm diameter) to remove
clumps and cellular aggregates and incubated for 15
min at 4º C on a rotator at 4 rpm with a human IgG
to block the Fc receptor and an anti-CD34 mouse
monoclonal antibody (MoAb) (QBEND-10) modified
with an hapten. Cells were washed once with selection
buffer and incubated for 20 min at 4ºC, 4 rpm, with
an anti-hapten mouse MoAb conjugated to colloidal
superparamagnetic microbeads (Miltenyi Biotec) and
filtered through a nylon mesh. The high gradient mag-
netic columns (MS columns, mini-MACS, Miltenyi
Biotec) were filled with 1 mL of cold selection buffer
before use. Labeled cells were applied and the
unbound cells were washed out with 0.5 mL  4 of
selection buffer. Positive cells were eluted from the col-
umn out side of the magnet with 1 mL of selection
buffer at high rate. A second column was used to
improve enrichment. All manipulations were per-
formed in a laminar flow hood. Cell viability was eval-
uated by the trypan blue dye exclusion and/or propid-
ium iodide tests. 
Flow cytometry
Samples were analyzed with an Epics-XL-MCL flow
cytometer (Coulter Electronic, Inc., Hialeah, FL, USA)
equipped with a 488 nm excitation Argon laser. MNC
and CD34+ enriched cells were incubated with AB
inactive human serum 1% (v/v) for 10 min at 4ºC.
Afterwards, cells were washed with HBS with 0.2%
of sodium-azide (Merck, Germany) and 2% of bovine
serum albumin (Sigma Chemical Co, Sant Louis,
USA) (HBS-BSA), centrifuged and diluted in a final
volume of 50 mL after tube decantation. Cells were
incubated with MoAbs for 30 min to 4ºC in the dark
at the concentration indicated by previous titration.
Samples were then washed twice in HBS-BSA and
incubated with 7-aminoactinomycin-D (7-AAD, Mol-
ecular Probes, Eugene, Oregon, USA) at 5 µg/mL for
5 min at room temperature. Cells were acquired by
setting an amorphous gate of forward side (FS) and
7-AAD, to exclude 7-AAD+ dead cells. A second gate
was established on FS and side scatter (SS) to include
cells with low SS and low to high FS. FS, SS (linear
amplification) and fluorescence signals (logarithmic
amplification) were determined for each cell (mini-
mum of 10,000 CD34 purified events per sample)
and stored in list mode data files. The following direct
phycoerythrin (PE) labeled MoAbs were used in a sin-
gle color: HPCA-2 (CD34, 8G12, IgG1), Leu8 (L-
selectin, CD62L, SK11, IgG2a), Leu54 (ICAM-1,
CD54, LB-2, IgG2b), 2 integrin (CD18, L130, IgG1),
N-CAM (Leu19, CD56, My31, IgG1), (Becton Dick-
inson, San José, FL, USA); ICAM-3 (CD50, HP2/19,
IgG2a), L-selectin (CD62L, Dreg56, IgG1), LFA-3
(CD58, AICD58, IgG2a) (Coulter Immunology,
Hialeah, FL, USA). Double staining with FITC-HPCA-
2 and PE-Leu8 was performed on 6 samples before
(MNC) and after the CD34+ cell selection including
also 7-AAD, to reveal whether L-selectin expression
pattern on CD34+ cells could be affected by the
enrichment procedure. Triple color immunofluores-
cence analysis was performed to determine the L-
selectin co-expression by CD34+/HLA-DR–/low and
CD34+/CD38–/low primitive progenitor cell subsets.
For these studies, purified CD34+ cells were simulta-
neously stained with MoAb to PerCP-anti-CD34
(HPCA-2-PerCP, Becton Dickinson), PE-anti-HLA-
DR (L246, IgG2a, Becton Dickinson) or PE-anti-
CD38 (T16, IgG1, Immunotech, SA) and FITC-anti-
Leu8 (Becton Dickinson). Negative controls with iso-
type non-relevant MoAb (mouse IgG1, IgG2a, Becton
Dickinson) were done in all experiments. Data from
20,000 to 30,000 CD34+ events were collected on
triple color studies. Gates defining stained cells were
set to include 1% of cells stained with the isotypic
control. Data analysis was performed with the Epics-
XL-MCL v. 1.5 workstation software (Coulter Elec-
tronic). 
Short-term cultures
The culture medium was composed of RPMI-1640
(GibcoBRL, Life Technologies Ltd, Paisley, Scotland)
with 20% fetal bovine serum (FBS), 100 U/mL peni-
cillin, and 100 µg/mL streptomycin.  Purified BM
CD34+ cells from 8 untreated CML patients as well as
the IFN- growth-sensitive Daudi B lymphoblastoid
cell line (obtained from ATCC) were incubated in vit-
ro with culture medium containing different concen-
trations of IFN-2b (100, 1,000, 5,000, 10,000
U/mL) (kindly supplied by Schering Plough, Madrid,
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Spain). Cells without IFN-2b added to the medium
were used as controls. Cells were plated in 96-well
round-bottomed plates (1-2105 cells per well, 0.5-
1106 cells/mL) and incubated at 37ºC with 5% CO2
for different times (24 h, 48 h and 72 h). Assays were
run in triplicate. After washing and blocking with AB
human serum, the cells were stained with PE-anti-
Leu8 MoAb or with isotypic control including 7-AAD
in all cases as previously described, then analyzed by
flow cytometry. 
Statistical analysis 
Data obtained by flow cytometry analysis are pre-
sented as the percentage of positive events. Quan-
tification of adhesion molecule expression was eval-
uated as the ratio of mean fluorescence intensity
between the test and the negative control histogram
(logarithmic scale) (MFI). Results of experimental
points obtained from multiple experiments are
reported as arithmetic mean and standard deviation
(s.d.). Normality of the parameters was evaluated by
the Kolmorov-Smirnov test. The Mann-Whitney U-
test was used to compare the expression of the adhe-
sion molecules. A p value lower than 0.05 was con-
sidered statistically significant.  
General linear-mixed models were used to estimate
the effect of IFN-2b on the expression of L-selectin
(percentage of positive events and MFI). These mod-
els allowed analysis of the overall effect, at any time
and any dose. The dose-effect relationship of IFN-
2b was also modeled, overall and in relation to the
incubation time. For these latter analyses, the loga-
rithm of the dose was used to improve homoscedas-
ticity. To ease interpretation of coefficients, decimal
logarithms were used, thus an increase in one unit of
log-dose corresponds to multiplying the dose by 10.
Time effect measured differences at 48 and 72 hours
of incubation with respect to 24 hours.  All models
included the subject as a random effect. The test for
a random effect for IFN-2b was not statistically sig-
nificant. Estimation of coefficients and standard
errors to compute 95% confidence intervals were
based on restricted maximum likelihood. Compar-
isons of models were based on likelihood ratio tests
derived from model fits using maximum likelihood
fit. All analyses were done with S-PLUS functions
using the library NLME.25
Results
Cell surface expression of the adhesion
molecules
The percentage of CD34+ cells after the selection
procedure and after gating the cell population to
exclude 7-AAD+ events and to include low SS and
variable FS was always superior to 95% (Figure 1). 
Co-expression of CAMs on purified CD34+ BM cells
is shown in Table 1. The percentage of CD34+ cells
expressing L-selectin was lower in CML than in con-
trols (25.4±12.8% Vs 68.7±8.3%, p<0.005) (Figure
2). L-selectin reactivity was measured before and after
the CD34+ selection procedure in 5 CML samples (2
untreated and 3 treated with IFN-) and 1 control,
to reveal whether this molecule could be affected by
the enrichment procedure. No differences were
shown in L-selectin before and after the CD34+
enrichment technique (30.4±27% vs 35±27%, respec-
tively, p=ns). L-selectin expression on CD34+ purified
cells was measured with another MoAb (Dreg56) in
some cases and was not different from that measured
with the antibody used in this study (Leu8) (data not
shown).
A subpopulation of CD34+/NCAM+ cells, not seen
in the BM of healthy adults was detected in 14 of 34
CML patients, representing more than 5% of the
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Figure 1. FACS analysis of a representative case of BM from
an untreated CML patient after CD34+ cell purification with
the MACS system. A) A region was drawn on 7 aminoactino-
mycin-D (7AAD) vs FS to exclude 7AAD+ dead cells (R1). B)
A second gate of SS Vs FS was drawn to include events with
low SS and low to high FS (R2).  C) The expression of CD34
was analyzed in the first histogram of FL2 (log scale). The
positive cells are cells stained above 1% of the negative
control (dashed line).
Figure 2. Expression of L-selectin on purified BM CD34+
cells by single color FACS analysis. The analysis was per-
formed as described in Figure 1. The percentages of posi-
tive events represent the cells stained above 1% of the neg-
ative control (dashed line). A) Normal control. B) Untreat-
ed CML.  
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CD34+ cells. Co-expression of ICAM-3 was higher in
CD34+ cells from CML patients than in those from
controls. No differences were shown with regards to
the expression of LFA-3, 2-integrin or ICAM-1.
The L-selectin expression rate was lower in hydroxy-
urea than in IFN- treated and untreated CML
patients (Table 1). A higher co-expression of NCAM
was found in untreated than in IFN- or hydroxyurea
treated patients. No differences were found with
respect to the others molecules analyzed. 
Eight of fifteen CML patients achieved some degree
of cytogenetic response after in vivo treatment with
IFN-. No differences were found between percent-
ages of adhesion molecule expression on CD34+ cells
between responding and non-responding patients.
Expression of CAMs in IFN- responding patients
was independent of the degree of cytogenetic
response. 
Expression of L-selectin on CD34+/CD38 and
CD34+/HLA-DR subpopulations
Purified CD34+ BM cells from 7 controls and 8
untreated CML patients were stained with MoAb to
Leu8, CD34 and CD38 or HLA-DR and analyzed by
three-color flow cytometry. After gating in FS/SS to
exclude debris, two regions were drawn on dot-plots
of FL2 vs FL3: CD34+/HLA-DR–/low or CD34+/CD38–/low
and CD34+/HLA-DR+ or CD34+/CD38+ (regions of
positive events were allowed to include 1% of the neg-
ative controls). Each fraction was evaluated for the
expression of L-selectin in histograms of FL1 (Table
2). The mean percentages of CD34+/HLA-DR–/low cells
were 1.8±1.1% in controls and 1.5±0.9% in CML
patients. CD34+/CD38–/low cells were expressed in
3.4±3.4% and 2.2±1.2% in controls and CML patients,
respectively. The cells expressing L-selectin in all CD34+
cell fractions (HLA-DR–/low, HLA-DR+, CD38–/low and
CD38+) from CML patients were significantly fewer
than those from controls. 
Short-term culture with IFN-
Analysis of the effect of IFN- on the cell surface
expression of L-selectin was first performed using the
Daudi cell line. This cell line constitutively expresses
low but detectable levels of L-selectin, with a mean-
expression  rate of 15%. This cell line has been report-
ed to increase L-selectin expression in response to in
vitro treatment with IFN-29 and was used in this
study as the positive control for the culture condi-
tions. Overall, in vitro treatment of the Daudi cell line
with IFN- increased the expression of L-selectin to
44.7%. (95% confidence interval [CI]=39.6,49.7).
This induced expression was dose-dependent with an
additional 11.7% ([CI]= 9.5,13.9) increment of the L-
selectin expression rate every time IFN-2b dosage
was increased 1 log. The effect was also time-depen-
dent with additional 20% ([CI]= 10.5,29.4) and
14.5% ([CI]= 7.1,21.8) increments at 48 h and 72 h
with respect to the 24 h culture. 
The incubation of CD34+ enriched cells from
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Table 1. Expression of cell adhesion molecules on purified bone marrow CD34+ cells from controls and chronic myeloid leukemia
patients.
L-selectin 2-integrin ICAM-1 ICAM-3 N-CAM LFA-3
n % MFI % MFI % MFI % MFI % MFI % MFI
Controls 15 68.7† 21.1† 48.9 6 31 2 93.3 104 1† 0.9 97 19 
(8.3) (12.2) (15) (2.7) (16) (0.8) (4.5) (61) (1.5) (0.0) (2) (10)
CML
Diagnosis 15 30.2†§ 2.7† 52.9 3.6 33.7 2.3 98.1† 144 19.4†# 1.7† 92.2 18 
(12) (1.6) (6.9) (0.5) (23.4) (1.5) (0.9) (63) (8) (0.4) (12) (1.4)
IFN- 15 22.3† 2.5† 49 4.3 22.1 1.6 96.8† 128 9.2†# 1.3† 92.3 18.7 
(11.9) (1.6) (35) (1.9) (17.2) (0.6) (4.3) (53) (8.9) (0.3) (11) (6.9)
Hydroxyurea 4 11.1†§ 1.9† 64 6.4 26 1.9 98† 144 10.6†# 1.1† 98.3 17.9 
(4.8) (0.6) (37) (1.3) (16) (0.5) (1.7) (4) (7.3) (0.0) (1.9) (3.9)
The expression of adhesion molecules is presented as percentage of positive events and MFI (ratio between mean fluorescence intensity of test and negative con-
trol histograms). Results are expressed as mean value and standard deviation. p < 0.05: comparison between †normal controls and CML patients; §hydroxyurea vs
CML at diagnosis and IFN- treated patients; #CML at diagnosis vs IFN- and hydroxyurea treated patients. 
Table 2. Co-expression of L-selectin molecule on CD34+ puri-
fied cells (HLA-DR or CD38) from untreated CML patients
and control group.
HLA-DR–/low HLA-DR+ CD38–/low CD38+
Untreated CML (n = 8)
Mean (SD) 27.4 (21.5) 24.8 (16.7) 39.8 (26.7) 21.2 (5.4)
Median (range) 20 (7-70) 23.5 (8-58) 38 (7-74) 23 (15-27)
Normal controls (n = 7)
Mean (SD) 61 (17) 71 (7) 83.7 (10) 67.1 (6.9)
Median (range) 60.5 (34-94) 72 (63-81) 83.7 (70-96) 65 (59-79)
p* 0.03 0.001 0.009 0.002
Percentage of L-selectin co-expression on CD34+/HLA-DR or CD38 fractions
as determined by triple color immunofluorescence analysis. The CML
patients and control group studied were 4 of the 15 cases and 7 of the 15
cases contributing to the data in table 1, respectively.
*Mann-Whitney U-test.
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untreated CML patients (n=8) with IFN-2b signifi-
cantly increased the percentage and fluorescence
intensity of L-selectin expression at any point of the
culture (Table 3). Overall, L-selectin expression rate
increased 8.3% with IFN- compared to cells cultured
without IFN-. This increase was dose-dependent
(with an additional 2.41% increment every time IFN-
2b dosage added to the culture was increased 1 log)
and time-dependent (with additional 2.84% and
14.11% increment at 48 h and 72 h vs 24 h of culture,
respectively). In contrast, no differences were shown
in L-selectin expression rate on CD34+ BM cells from
normal controls (n= 2) between cultured cells with-
out or with IFN- (overall expression and MFI of
74.8% [CI] = 62.91, 86.73 vs 75.0% [CI] = 59.1,90.9,
p = 0.9, and 15.05 [CI] = 7.22, 22.88 vs  15.66 [CI]
= 7.19,24.12, p = 0.6, respectively).
Discussion
In this report we show that L-selectin adhesion
receptor is abnormally co-expressed on CD34+ BM-
cells from CML patients at a mean of ten fold lower
fluorescence intensity than normal controls. In addi-
tion, the mean percentage of CD34+ cells expressing L-
selectin from CML patients treated with hydroxyurea
was lower than that from IFN- treated or untreated
patients. Since CML is a stem cell disorder, we further
studied the L-selectin expression pattern in untreated
CML patients on a more primitive progenitor cell sub-
set as defined by the expression of CD34+ and the lack
co-expression of HLA-DR or CD38 antigens. Triple-
color flow cytometry analysis demonstrated that
CD34+/CD38–/low and CD34+/CD38+ also co-
expressed significantly lower percentages of L-selectin
than control cells. This finding is in agreement with
results from Kawaishi et al.5 who have recently report-
ed a lower expression rate of L-selectin on
CD34+/CD38+ cells from untreated CML patients. Our
data also show that the CD34+/CD38–/low subpopula-
tion has a significantly lower mean percentage of L-
selectin expression than normal controls. With regards
to HLA-DR antigen expression, both CD34+ cell sub-
populations, HLA-DR–/low and HLA-DR+, also co-
expressed lower percentages of L-selectin than con-
trols. CD34+/HLA-DR–/low, but not CD34+/CD38–/low
fractions, have been reported to be enriched in benign
progenitors in CML patients.26-28 Thus, one could
speculate that this primitive CD34+/CD38–/low cell sub-
set might be predominantly malignant CML progeni-
tors expressing lower L-selectin. However, a similar
expression rate of L-selectin in CML and controls
could be expected in the CD34+/HLA-DR–/low fraction.
One possible interpretation for these observations is
that the CD34+/HLA-DR–/low cell fraction expressing
lower L-selectin might be expanded in CML.  Another
explanation could be the variability of the proportion
of normal progenitors in these fractions.
We next investigated the effect of IFN- in vitro
treatment of purified CD34+ cells from untreated
CML patients on the abnormally co-expressed L-
selectin molecule. Our data show that L-selectin
expression was significantly up-regulated on CML
CD34+ cells upon in vitro culture with IFN-. Approx-
imately, 10-20% of the BM CD34+ cells were found to
increase L-selectin expression rate in response to IFN-
 treatment. This effect was dose- and time-depen-
dent. Similarly, IFN- was also found to induce L-
selectin expression on the human B-lymphoid Daudi
cell line in a dose and time-dependent manner, which
is in agreement with results published by Evans et al.29
concerning this cell line. Of note, L-selectin enhance-
ment on the cell surface of the Daudi cell line was
much more marked than that observed on CML
CD34+ cells with a rate increased to nearly 50% over
the control cells without IFN-. Therefore, the pro-
portion of CD34+ BM cells from CML responding to
IFN- appears to be relatively restricted and is simi-
lar to that reported for tissue-derived human B-
cells.29 In addition, no effect was shown on CD34+
cells treated with IFN- in vitro from normal controls.
These data may suggest that the effect of IFN- in vit-
IFN- modulates L-selectin expression on CML CD34+ cells
Table 3. Effect of in vitro treatment with interferon-2b (IFN)
on the expression of L-selectin on bone marrow CD34+ puri-
fied cells from CML patients.
L-selectin (%) MFI
Variable Coefficient CI95% Coefficient CI95%
Model 1
Intercept 35.72 (26.35,45,09) 2.66 (1.91,3.40)
IFN
No 0 0
Yes 8.37 (6.09,10.65) 0.68 (0.50,0.86)
Random patient 249.50 1.43
(variance)
Model 2
Intercept 30.54 (19.96,41.12) 2.45 (1.65,3.25)
Doses IFN (log10) 2.41 (1.76,3.06) 0.19 (0.13,0.25)
Time
24 h 0 0
48 h 2.84 (0.37,5.31) 0.31 (0.11,0.51)
72 h 14.11 (10.50,17.72) 0.47 (0.18,0.76)
Random patient 249.42 1.45
(variance)
Increased expression rate and mean fluorescence intensity (MFI) of L-selectin
on purified CD34+ bone marrow cells from untreated CML patients at diagno-
sis (n=8) after in vitro treatment with interferon-2b (IFN-2b). The patients
investigated were 2 and 1 of the cases contributing to the data in Tables 2
and 3, respectively, plus 5 further cases who were studied only for the effect
of the in vitro treatment with IFN- on the expression of L-selectin. Purified
CD34+ cells incubated with or without IFN-2b at different doses and times,
were labeled with antibodies to the L-selectin (leu8) or with isotypic control,
including 7-AAD. The expression of L-selectin was measured using FACS
analysis. MFI represents the ratio between the MFI of the test and the isotypic
control histograms (log scale). Statistical analysis was done using general lin-
ear-mixed models. Model 1 estimates the effect of in vitro treatment with IFN-
2b for all times and doses. Model 2 estimates the effect of different doses
and time. The coefficient, confidence interval 95% (CI95%) and the variance
interpatients (random patient) are shown. IFN-2b increases the overall
expression rate of L-selectin on CD34+ purified cells by 8.37% and the MFI by
0.68. The effect was dose-dependent, with an additional 2.41% of increase in
the expression rate every time the dose of IFN-2b added to the culture was
increased 1 log. The effect was also time-dependent, with an additional
increase of 2.8% and 14% with respect to 24 h of culture after 48 h and 72 h
of incubation. 
ro is specific to CD34+ cells from patients with CML. 
IFN- treatment in CML can result in the selective
suppression of malignant hemopoietic progenitor cells
and restoration of normal hematopoiesis.20-22 The IFN-
 action mechanism in CML is unknown, but recent
in vitro studies have demonstrated that IFN- increas-
es the adhesion of CML progenitors to stroma. Such
an effect has been shown via an action of IFN- on
stroma cells23 and on CML progenitors correcting the
deficient expression and/or function of some CAMs.7,8
Bathia et al.7 demonstrated that IFN- partially
restored the adhesion of CML progenitor cells to BM
stroma by correcting 1-integrin receptor functions.
Kawaishi et al.6 reported an inverse correlation
between L-selectin expression rate in the CD34++/
CD38– cells of CML patients and the percentage of
Ph’+ve cells in patients treated with IFN-. They specu-
late that this cell subpopulation could be restored to
normal in these patients or that IFN- may directly
induce L-selectin expression on CML CD34+ cells. The
data presented in this study suggest that IFN- acts on
CML progenitors to up-regulate L-selectin surface
expression and thus, may potentially use this adhe-
sion receptor to increase adhesive interactions
between CML progenitors and stroma. Nevertheless,
this in vitro effect of IFN- is partial and other mecha-
nism(s) that explain the beneficial effect of this drug
in CML patients are possible.30
The L-selectin molecule belongs to a new family of
selectin receptor adhesion molecules expressed on
neutrophils, monocytes, T, B and natural killer cells, in
addition to hematopoietic progenitor cells. L-selectin
is involved in the regulation of leukocyte traffic, and in
both initial attachment and rolling of lymphocytes and
neutrophils to endothelium.13 Although the function
of L-selectin on normal and CML hematopoietic prog-
enitors remains unknown, accumulated evidence sug-
gests that it plays a role in progenitor adhesion.13,31,32
Malignant progenitor cells from CML have defective
adhesion to BM stroma and this has been reported to
be partially mediated by dysfunction of 1-integrins,
since CML progenitor cells co-express similar levels of
this molecule to the levels expressed by normal prog-
enitor cells.7 It has also been  demonstrated that sig-
naling through L-selectin serves as an activation/prim-
ing step on leukocyte adhesion and facilitates subse-
quent firm cell-cell adhesion through 1-integrin dur-
ing an inflammatory response.33 Based on these data,
we speculate that the decreased L-selectin expression
on CD34+ cells from CML patients may make initial
cell attachment to stroma defective and thus, these
progenitors might not be capable of generating signals
to activate pathways that firmly attach progenitors to
the BM microenvironment. Up-regulation of L-selectin
expression in CML progenitors by IFN- treatment
could subsequently result in an enhanced affinity of
the normally co-expressed 1-integrin receptors.
A subset of CD34+ CML cells (6-26%) expressed
significant amounts of NCAM on their surface. By
contrast, this adhesion receptor was co-expressed by
less than 1% of purified CD34+ cell from normal indi-
viduals. These data are in agreement with those pre-
viously reported by Lanza et al.34 who also observed
a NCAM subpopulation within the CD34+ cells from
20% of CML patients. 
Most of the CD34+ BM cells from normal and CML
patients co-expressed LFA-3. Upadhyaya et al.8 have
reported a deficient expression of LFA-3 on progeni-
tor cells from untreated CML patients. They used a
panning technique and clonogeneic assays and
recovered only 20% of CML progenitor cells in the
adherent-LFA-3-positive fraction. In this work, using
a CD34+ cell selection technique and a flow cytome-
try approach, more than 90% of CD34+ cells from
CML co-expressed this molecule. Our results are in
agreement with those reported by Dowding et al.23
who were also unable to detect deficient LFA-3
expression on CD34+ cells from CML patients. 
ICAM-3, a counter-receptor for LFA1,35 was co-
expressed in more than 90% of CD34+ cells from CML
patients and controls. The slightly higher expression
rate of ICAM-3 in CML CD34+ cells demonstrated in
our study may reflect differences in cell populations
between CML patients and normal controls. We have
previously shown that CD34+/CD19+ putative B prog-
enitor cells comprise a very small proportion of CD34+
cells in CML patients,36 a cell subset with a lower per-
centage of ICAM-3 expression (data not shown).
In conclusion, the present study demonstrates that
L-selectin is deficiently co-expressed by CD34+ cells
from CML patients and that expression of this mol-
ecule is enhanced after in vitro treatment with IFN-.
The role of the partial restoration of L-selectin expres-
sion in re-establishing adhesive interactions abetween
CML progenitors and BM stroma deserves further
investigations.
Contributions and Acknowledgments
GAMH was the principal investigator, designed the study,
conducted the experiments, interpreted the data and wrote
the paper. RQ helped to conduct the experiments, and col-
lected and interpreted the data. JRG and VM designed and
performed the statistical study. AS was responsible for clini-
cal day-to-day management of the patients and critically
reviewed the manuscript; JG critically reviewed the different
versions of the manuscript. 
The order of the authors tries to take into account the time,
work and scientific contribution given by all the authors the
first author being the idea promoter and the last the senior
member of the research group. 
The authors wish to thank the Departments of Hematol-
ogy of the Hospital Santa Creu i Sant Pau and the Hospital
Princeps d’Espanya for supplying the bone marrow samples. 
Funding
This work was partially supported by a grant from the
“Ministerio de Educación y Cultura, Dirección General de
Enseñanza Superior y Investigación cientifica, SAF 98-0050.”
Schering-Plough kindly supplied the IFN-2b and partial-
ly supported the work. 
Part of this work was awarded the first prize “Modifi-
cadores de la Respuesta Biólogica en Hemopatías Malignas”
from Schering-Plough in the XIL National Meeting of the
Spanish Society of Hematology and Hemostasia which took
place in October 1997 in Barcelona, Spain.  
Disclosures
Conflict of interest: none.
Redundant publications: no substantial overlapping with
previous papers.
144
Haematologica vol. 85(2):February 2000
G. A. Martín-Henao et al.
145
Haematologica vol. 85(2):February 2000
IFN- modulates L-selectin expression on CML CD34+ cells
Manuscript processing
Manuscript received June 22, 1999; accepted October 29,
1999.
References
1. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chron-
ic myelocytic leukemia: clonal origin in a stem cell
common to the granulocyte, erythrocyte, platelet and
monocyte/macrophage. Am J Med 1977; 63:125-30.
2. Nowell PC, Hungerford DA. A minute chromosome in
human chronic granulocytic leukemia. Science 1960;
132:1497.
3. Goldman JM, Shiota F, Th’ng KH, Orchard KH. Cir-
culating granulocytic and erythroid progenitor cells in
chronic granulocytic leukaemia. Br J Haematol 1980;
46:7-13.
4. Gordon MY, Dowding CR, Riley GP, Goldman JM,
Greaves MF. Altered adhesive interactions with mar-
row stroma of haematopoietic progenitor cells in
chronic myeloid leukaemia. Nature 1987; 328:342-4.
5. Verfaillie CM, McCarthy JB, McGlave PB. Mechanisms
underlying abnormal trafficking of malignant progen-
itors in chronic myelogenous leukemia. Decreased
adhesion to stroma and fibronectin but increased
adhesion to the basement membrane components
laminin and collagen type IV. J Clin Invest 1992; 90:
1232-41.
6. Kawaishi K, Kimura A, Katoh O, et al. Decreased L-
selectin expression in CD34-positive cells from
patients with chronic myelocytic leukaemia. Br J
Haematol 1996; 93:367-74.
7. Bhatia R, Wayner EA, McGlave PB, Verfaillie CM.
Interferon- restores normal adhesion of chronic
myelogenous leukemia hematopoietic progenitors to
bone marrow stroma by correcting impaired 1 inte-
grin receptor function. J Clin Invest 1994; 94:384-91.
8. Upadhyaya G, Guba SC, Sih SA, et al. Interferon-
restores the deficient expression of the cytoadhesion
molecule lymphocyte function antigen-3 by chronic
myelogenous leukemia progenitor cells. J Clin Invest
1991; 88:2131-6.
9. Zannettino AC, Buhring HJ, Niutta S, Watt SM, Ben-
ton MA, Simmons PJ. The sialomucin CD164 (MGC-
24v) is an adhesive glycoprotein expressed by human
hematopoietic progenitors and bone marrow stromal
cells that serves as a potent negative regulator of
hematopoiesis. Blood 1998; 92:2613-28.
10. Verfaillie C, Blakolmer K, McGlave P. Purified primitive
human hematopoietic progenitor cells with long-term
in vitro repopulating capacity adhere selectively to irra-
diated bone marrow stroma. J Exp Med 1990; 172:
509-12.
11. Simmons PJ, Masinovsky B, Longenecker BM, Beren-
son R, Torok-Storb B, Gallatin WM. Vascular cell
adhesion molecule-1 expressed by bone marrow stro-
mal cells mediates the binding of hematopoietic prog-
enitor cells. Blood 1992; 80:388-95.
12. Teixido J, Hemler ME, Greenberger JS, Anklesaria P.
Role of 1 and 2 integrins in the adhesion of human
CD34hi stem cells to bone marrow stroma. J Clin Invest
1992; 90:358-67.
13. Kansas GS. Selectins and their ligands: current con-
cepts and controversies. Blood 1996; 88:3259-87.
14. Ghaffari S, Dougherty GJ, Lansdorp PM, Eaves AC,
Eaves CJ. Differentiation-associated changes in CD44
isoform expression during normal hematopoiesis and
their alteration in chronic myeloid leukemia. Blood
1995; 86:2976-85.
15. Healy L, May G, Gale K, Grosveld F, Greaves M, Enver
T. The stem cell antigen CD34 functions as a regula-
tor of hemopoietic cell adhesion. Proc Natl Acad Sci
U S A 1995; 92:12240-4.
16. Bazil V, Brandt J, Chen S, et al. A monoclonal antibody
recognizing CD43 (leukosialin) initiates apoptosis of
human hematopoietic progenitor cells but not stem
cells. Blood 1996; 87:1272-81.
17. Hurley RW, McCarthy JB, Verfaillie CM. Direct adhe-
sion to bone marrow stroma via fibronectin receptors
inhibits hematopoietic progenitor proliferation. J Clin
Invest 1995; 96:511-9.
18. Gordon MY, Atkinson J, Clarke D, et al. Deficiency of
a phosphatidylinositol-anchored cell adhesion mole-
cule influences haemopoietic progenitor binding to
marrow stroma in chronic myeloid leukaemia.
Leukemia 1991; 5:693-8.
19. Lundell BI, McCarthy JB, Kovach NL, Verfaillie CM.
Activation-dependent 51 integrin-mediated adhe-
sion to fibronectin decreases proliferation of chronic
myelogenous leukemia progenitors and K562 cells.
Blood 1996; 87:2450-8.
20. Allan NC, Richards SM, Shepherd PC. UK Medical
Research Council randomised, multicentre trial of
interferon- n1 for chronic myeloid leukaemia:
improved survival irrespective of cytogenetic response.
The UK Medical Research Council’s Working Parties
for Therapeutic Trials in Adult Leukaemia. Lancet
1995; 345:1392-7.
21. Hehlmann R, Heimpel H, Hasford J, et al. Random-
ized comparison of interferon- with busulfan and
hydroxyurea in chronic myelogenous leukemia. The
German CML Study Group. Blood 1994; 84: 4064-77.
22. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM,
Keating MJ, Gutterman JU. Hematologic remission
and cytogenetic improvement induced by recombi-
nant human interferon- in chronic myelogenous
leukemia. N Engl J Med 1986; 314:1065-9.
23. Dowding C, Guo AP, Osterholz J, Siczkowski M, Gold-
man J, Gordon M. Interferon- overrides the deficient
adhesion of chronic myeloid leukemia primitive prog-
enitor cells to bone marrow stromal cells. Blood 1991;
78:499-505.
24. Martin-Henao GA, Ingles-Esteve J, Cancelas JA, Gar-
cia J. Isolation of CD34+ hematopoietic progenitor
cells in chronic myeloid leukemia by magnetic acti-
vated cell sorting (MACS). Bone Marrow Transplant
1996; 18:603-9.
25. Pinheiro JC, Bates DM. Mixed-effect methods and
classes for S and S-PLUS. Bell Labs, Lucent Technolo-
gies and University of Wisconsin, Madison, 1998.
Potential implications for clinical practice
 Biological characterization of CML progenitors
will allow a more profound understanding of the
behavior of this disease which will make other
therapeutic approaches possible in patients not
candidates for allogeneic stem cell transplanta-
tion.
 -interferon constitutes one of the basic tools in
the clinical management of CML patients and its
mechanism of action is still unknown; the fact
that -interferon up-regulates L-selectin expres-
sion in CD34+ cells of CML patients sheds new
light on this issue.
 The up-regulation of L-selectin expression by -
interferon could be evaluated as a predictive test
to know whether a patient will achieve a cytoge-
netic response before starting the treatment.
146
Haematologica vol. 85(2):February 2000
26. Verfaillie CM, Miller WJ, Boylan K, McGlave PB. Selec-
tion of benign primitive hematopoietic progenitors in
chronic myelogenous leukemia on the basis of HLA-
DR antigen expression. Blood 1992; 79:1003-10.
27. Leemhuis T, Leibowitz D, Cox G, et al. Identification
of BCR/ABL-negative primitive hematopoietic prog-
enitor cells within chronic myeloid leukemia marrow.
Blood 1993; 81:801-7.
28. Kirk JA, Reems JA, Roecklein BA, et al. Benign marrow
progenitors are enriched in the CD34+/HLA-DRlo pop-
ulation but not in the CD34+/CD38lo population in
chronic myeloid leukemia: an analysis using interphase
fluorescence in situ hybridization. Blood 1995; 86:
737-43.
29. Evans SS, Collea RP, Appenheimer MM, Gollnick SO.
Interferon- induces the expression of the L-selectin
homing receptor in human B lymphoid cells. J Cell Biol
1993; 123:1889-98.
30. Gordon MY, Marley SB, Lewis JL, et al. Treatment with
interferon- preferentially reduces the capacity for
amplification of granulocyte-macrophage progenitors
(CFU-GM) from patients with chronic myeloid
leukemia but spares normal CFU-GM. J Clin Invest
1998; 102:710-5.
31. Oxley SM, Sackstein R. Detection of an L-selectin lig-
and on a hematopoietic progenitor cell line. Blood
1994; 84:3299-306.
32. Mohle R, Moore MA, Nachman RL, Rafii S. Trans-
endothelial migration of CD34+ and mature hemato-
poietic cells: an in vitro study using a human bone
marrow endothelial cell line. Blood 1997; 89:72-80.
33. Steeber DA, Engel P, Miller AS, Sheetz MP, Tedder TF.
Ligation of L-selectin through conserved regions with-
in the lectin domain activates signal transduction
pathways and integrin function in human, mouse, and
rat leukocytes. J Immunol 1997; 159:952-63.
34. Lanza F, Bi S, Castoldi G, Goldman JM. Abnormal
expression of N-CAM (CD56) adhesion molecule on
myeloid and progenitor cells from chronic myeloid
leukemia. Leukemia 1993; 7:1570-5.
35. de Fougerolles AR, Springer TA. Intercellular adhesion
molecule 3, a third adhesion counter-receptor for lym-
phocyte function-associated molecule 1 on resting
lymphocytes. J Exp Med 1992; 175:185-90.
36. Martín-Henao GA, Quiroga R, Sureda A, García J.
CD7 expression on CD34+ cells from chronic myeloid
leukaemia in chronic phase. Am J Hematol 1999;
61:178-86.
G. A. Martín-Henao et al.
